{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:42:50Z","timestamp":1787240570165,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.revmed.2019.02.005","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T08:39:23Z","timestamp":1552034363000},"page":"368-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Azithromycine et pathologies bronchiques chroniques\u00a0: quels patients\u00a0? Quels b\u00e9n\u00e9fices\u00a0? Quelles modalit\u00e9s\u00a0?"],"prefix":"10.1016","volume":"40","author":[{"given":"P.","family":"Pronost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tromeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2019.02.005_bib0125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2019.02.005_bib0130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00136712","article-title":"Long-term macrolide treatment for chronic respiratory disease","volume":"42","author":"Spagnolo","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2019.02.005_bib0135","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2019.02.005_bib0140","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2019.02.005_bib0145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2019.02.005_bib0150","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.chest.2018.01.044","article-title":"Clinical and safety outcomes of long-term azithromycin therapy in severe COPD beyond the first year of treatment","volume":"153","author":"Pomares","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2019.02.005_bib0155","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.rmr.2016.10.004","article-title":"Pharmacological treatment optimization for stable chronic obstructive pulmonary disease. Proposals from the Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise","volume":"33","author":"Zysman","year":"2016","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.revmed.2019.02.005_bib0160","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2019.02.005_bib0165","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2019.02.005_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2004.09.014","article-title":"Macrolides in the treatment of asthma and cystic fibrosis","volume":"99","author":"Ferrara","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.revmed.2019.02.005_bib0175","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.revmed.2019.02.005_bib0180","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2019.02.005_bib0185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1183\/09031936.00068310","article-title":"A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation","volume":"37","author":"Vos","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2019.02.005_bib0190","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejim.2005.12.003","article-title":"Torsades de pointes induced by antibiotics","volume":"17","author":"Justo","year":"2006","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.revmed.2019.02.005_bib0195","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/11531850-000000000-00000","article-title":"Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA adverse event reporting system","volume":"33","author":"Poluzzi","year":"2010","journal-title":"Drug Saf"},{"key":"10.1016\/j.revmed.2019.02.005_bib0200","doi-asserted-by":"crossref","first-page":"1362e1","DOI":"10.1016\/j.amjmed.2015.07.032","article-title":"Azithromycin for the prevention of COPD exacerbations: the good, bad, and ugly","volume":"128","author":"Taylor","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2019.02.005_bib0205","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.revmed.2019.02.005_bib0210","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/000348940010900416","article-title":"Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity: a case report","volume":"109","author":"Ress","year":"2000","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.revmed.2019.02.005_bib0215","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jac\/dkq425","article-title":"Characterization of macrolide resistance genes in Haemophilus influenzae isolated from children with cystic fibrosis","volume":"66","author":"Roberts","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.revmed.2019.02.005_bib0220","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcf.2008.09.001","article-title":"Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients","volume":"8","author":"Hansen","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.revmed.2019.02.005_bib0225","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1086\/374937","article-title":"High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains","volume":"187","author":"Prunier","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.revmed.2019.02.005_bib0230","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1128\/AAC.01845-09","article-title":"Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients","volume":"54","author":"Grinwis","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.revmed.2019.02.005_bib0235","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2019.02.005_bib0120","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.lpm.2013.08.006","article-title":"Macrolides au long cours et pathologie bronchique chronique de l\u2019adulte\u00a0: int\u00e9r\u00eats et limites","volume":"43","author":"Jouneau","year":"2014","journal-title":"Presse Med"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319300530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319300530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:40:34Z","timestamp":1759336834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866319300530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0248866319300530"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2019.02.005","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azithromycine et pathologies bronchiques chroniques\u00a0: quels patients\u00a0? Quels b\u00e9n\u00e9fices\u00a0? Quelles modalit\u00e9s\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2019.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}